We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results:1-10 of 539

USPTO Says Overlapping Range In Prior Art Insufficient to Invalidate Method of Treatment Patent
  • Dechert LLP
  • USA
  • April 13 2018

Pharmaceutical patents frequently claim treatment methods that utilize a range of amounts or concentrations for the active ingredient or excipients

Sham Affidavits
  • Reed Smith LLP
  • USA
  • September 25 2017

We're quite familiar with people who say one thing, when they think that's in their interest, and later when circumstances change, say something

The Power of an Inference: Federal Court Restores $125 Million S. 8 Damages Award
  • McCarthy Tétrault LLP
  • Canada
  • June 16 2017

In Teva v. Pfizer Canada, 2017 FC 526, the Federal Court reaffirmed and reissued a judgment awarding Teva a section 8 damages award in excess of $125

  • Wanhuida Peksung IP Group
  • China
  • May 19 2017


2016 False Claims Act Review: A Truly Extraordinary Year
  • Pietragallo Gordon Alfano Bosick & Raspanti LLP
  • USA
  • April 1 2017

As we head into the second quarter of an already turbulent 2017, it is worth reflecting on the truly extraordinary events of 2016. Of course, there

Where Party Joined Pending IPRs, Delaware Takes Broad View of 315 Estoppel
  • Jones Day
  • USA
  • March 10 2017

In Parallel Networks Licensing, LLC v. International Business Machines Corporation, No. 1:13-cv-02072, Dkt. No. 366 (D. Del. Feb. 22, 2017) (Slip Op

IPR Estoppel Provisions May Not Be That Scary After All
  • Pepper Hamilton LLP
  • USA
  • February 21 2017

IPR petitioners wary of the statutory estoppel under 35 U.S.C. 315(e)(2) may have reason to be cautiously optimistic. Judge Sue Robinson of

District Court Interprets the IPR Estoppel Provision Narrowly
  • Marshall Gerstein & Borun LLP
  • USA
  • December 28 2016

An AIA trial is a relatively-inexpensive, partial substitute for challenging the validity of a patent. Yet, prospective AIA trial petitioners

Federal Circuit Affirms Tygacil Formulation Patent
  • Foley & Lardner LLP
  • USA
  • August 23 2016

In Apotex, Inc. v. Wyeth LLC, the Federal Circuit affirmed the decision of the USPTO Patent Trial and Appeal Board (PTAB) finding that Apotex had

Federal Circuit Affirms PTAB Upholding Patent Claims
  • Marshall Gerstein & Borun LLP
  • USA
  • August 23 2016

In what has been a rare outcome to date, the Federal Circuit in Apotex v. Wyeth, dkt. no. 2015-1871 (Fed. Cir. Aug. 16, 2016) affirmed in a